Molecular Imaging 2017

/ 23 22

Cost-effectiveness

Is PET-CT guided management for patients with locally advanced head and neck squamous cell cancer (HNSCC) cost-effective? Results from a UK non-inferiority phase III randomized trial. Smith et al., University of Leeds, J Clin Oncol 33, 2015 (suppl; abstr 6010) Evaluation Individual patient data evaluation for NHS reimbursement (564). Comparison of randomized arms for 2Y cost-effectiveness.

Outcome for intervention arm Average health benefit 0.07 QALYs Average cost saving 1415 GBP Probabilities at 20.000 GBP per QALY PET/CT = cheaper 99% PET/CT = most effective 91% PET/CT = most cost-effective 98%